Clinical trials: Weight Change
Obesity &Amp;Amp;Amp; Overweight, Environmental Exposure
Weight Loss and Endocrine Disrupting Chemicals (EDCs): Lifestyle Interventions to Lose Weight and Reduce EDC Exposure in Individuals With Overweight/Obesity
The goal of this study is to examine the relationship in individuals with overweight/obesity and endocrine disrupting chemical (EDC) exposure through a two-armed, randomized clinical trial.
- Conditions
- Obesity &Amp;Amp;Amp; Overweight, Environmental Exposure, Overweight (BMI > 25)
- Trial name
- LiveWell (NCT07560579)
- Testing
- Educational curriculum, Weight loss Application, Urinary EDC metabolite testing
- Where
- United States
- Volunteers
- 226 people
- Sponsor
- Million Marker Wellness, Inc.
Type 2 Diabetes Mellitus, Weight Loss
A Clinical Study of Mass Balance of [14C]HRS-7535
The objective is to evaluate the mass balance of [14C]HRS-7535 in healthy adult Chinese subjects.
- Trial name
- NCT06819488
- Testing
- [14C]HRS-7535
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Weight Loss
Safety and Efficacy of IQP- AK-102 in Reducing Body Weight
The individual ingredients in IQP-AK-102 have been widely used. Backed by data from several studies demonstrating their efficacy, we are conducting this study to look into the efficacy and safety of this novel combination of…
- Trial name
- NCT01905956
- Testing
- IQP-AK-102
- Where
- Germany
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Psoriasis
Post-Marketing Surveillance Study of OTEZLA
To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients with Psoriasis vulgaris that is with an inadequate response to topical therapies and Psoriasis arthropathica 1.
- Trial name
- NCT03284879
- Where
- Japan
- Volunteers
- 1,086 people
- Sponsor
- Amgen
Obesity
A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-06882961) for the potential treatment of obesity.
- Trial name
- NCT04707313
- Testing
- PF-06882961 (Cohorts 1 and 2), PF-06882961 (Cohort 3)
- Where
- 41 sites in United States, Canada and 2 more
- Volunteers
- 628 people
- Sponsor
- Pfizer
Overweight
Survey on the Pharmacy Follow-up of Alli Purchasers
To assess the feasibility and acceptability of genuine pharmacy follow up of people wishing to lose weight.
- Trial name
- NCT01387243
- Testing
- Orlistat
- Volunteers
- 80 people
- Sponsor
- GlaxoSmithKline